BENDAMUSTINE MYLAN 2.5 mg/ml, powder for concentrate for infusion 5 bottles
Active ingredients: Bendamustine hydrochloride monohydrate, Bendamustine hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Powder for concentrate for infusion5 bottlesintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BENDAMUSTINE MYLAN 2,5 mg/ml, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 5 flacon(s) en verre brun de 100 mg de poudre
- Marketing authorisation holder
- MYLAN SAS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 28 Mar 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60295427CIP75502673CIP133400955026730Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BENDAMUSTINE (CHLORHYDRATE DE) MONOHYDRATÉpoudre | — | SA |
| CHLORHYDRATE DE BENDAMUSTINEpoudre | 25 mg · un flacon de 20 mL | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.